CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by El-Badry, O. M.
Right arrow Articles by Helman, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by El-Badry, O. M.
Right arrow Articles by Helman, L. J.

Cell Growth & Differentiation, Vol 1, Issue 7 325-331, Copyright © 1990 by American Association of Cancer Research


ARTICLES

Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors

OM El-Badry, C Minniti, EC Kohn, PJ Houghton, WH Daughaday and LJ Helman
Pediatric Branch, National Cancer Institute, Bethesda, Maryland 20892.

Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood and appears to arise from developing striated muscle-forming cells. Since insulin-like growth factor II (IGF-II) is involved in normal muscle growth and maturation and elevated IGF-II mRNA levels have previously been reported in rhabdomyosarcomas, we have been studying the possible role of IGF-II in the unregulated growth and invasive potential of these embryonal tumors. In this study, we demonstrate that 13 of 14 rhabdomyosarcoma tumors express high levels of IGF-II mRNA relative to normal adult muscle and also express mRNA for the type I IGF receptors on their cell surface, the receptor thought to mediate the effects of IGF-II on muscle cells. We have established several rhabdomyosarcoma cell lines in mitogen-free media and demonstrate that these cells express type I IGF receptors on their cell surface and secrete IGF-II into the media. Exogenous IGF-II is able to stimulate cellular motility in these cell lines as assayed in a modified Boyden chamber. Finally, alpha IR-3, a type I receptor antagonist, inhibits the growth of these cell lines in serum-free media but does not inhibit IGF-II-induced motility of these cells. These data suggest that endogenously produced IGF-II functions as an autocrine growth and motility factor in many rhabdomyosarcoma tumors. The mitogenic actions of IGF-II are mediated through a domain of the type I IGF receptor that is blocked by alpha IR-3. IGF-II-induced motility may be mediated through an alternative signaling pathway.


This article has been cited by other articles:


Home page
Mol Cancer ResHome page
G. Schneider, Z. P. Sellers, A. Abdel-Latif, A. J. Morris, and M. Z. Ratajczak
Bioactive Lipids, LPC and LPA, Are Novel Prometastatic Factors and Their Tissue Levels Increase in Response to Radio/Chemotherapy
Mol. Cancer Res., November 1, 2014; 12(11): 1560 - 1573.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Zhong, C. Fazenbaker, S. Breen, C. Chen, J. Huang, C. Morehouse, Y. Yao, and R. E. Hollingsworth
MEDI-573, Alone or in Combination with Mammalian Target of Rapamycin Inhibitors, Targets the Insulin-like Growth Factor Pathway in Sarcomas
Mol. Cancer Ther., November 1, 2014; 13(11): 2662 - 2673.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. K. Bid, C. A. London, J. Gao, H. Zhong, R. E. Hollingsworth, S. Fernandez, X. Mo, and P. J. Houghton
Dual Targeting of the Type 1 Insulin-like Growth Factor Receptor and Its Ligands as an Effective Antiangiogenic Strategy
Clin. Cancer Res., June 1, 2013; 19(11): 2984 - 2994.
[Abstract] [Full Text] [PDF]


Home page
Clin. Sci.Home page
L. A. Bach, P. Fu, and Z. Yang
Insulin-like growth factor-binding protein-6 and cancer
Clin. Sci., February 1, 2013; 124(4): 215 - 229.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. K. Bid, J. Zhan, D. A. Phelps, R. T. Kurmasheva, and P. J. Houghton
Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2
Mol. Cancer Ther., March 1, 2012; 11(3): 649 - 659.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Malempati, B. Weigel, A. M. Ingle, C. H. Ahern, J. M. Carroll, C. T. Roberts, J. M. Reid, S. Schmechel, S. D. Voss, S. Y. Cho, et al.
Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group
J. Clin. Oncol., January 20, 2012; 30(3): 256 - 262.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. Abraham, S. I. Prajapati, K. Nishijo, B. S. Schaffer, E. Taniguchi, A. Kilcoyne, A. T. McCleish, L. D. Nelon, F. G. Giles, A. Efstratiadis, et al.
Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma
Mol. Cancer Ther., April 1, 2011; 10(4): 697 - 707.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. C. Potratz, D. N. Saunders, D. H. Wai, T. L. Ng, S. E. McKinney, J. M. Carboni, M. M. Gottardis, T. J. Triche, H. Jurgens, M. N. Pollak, et al.
Synthetic Lethality Screens Reveal RPS6 and MST1R as Modifiers of Insulin-like Growth Factor-1 Receptor Inhibitor Activity in Childhood Sarcomas
Cancer Res., November 1, 2010; 70(21): 8770 - 8781.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
P. Nanni, G. Nicoletti, A. Palladini, A. Astolfi, P. Rinella, S. Croci, L. Landuzzi, G. Monduzzi, V. Stivani, A. Antognoli, et al.
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4
Mol. Cancer Ther., April 1, 2009; 8(4): 754 - 761.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
S. Y. Kim, J. A. Toretsky, D. Scher, and L. J. Helman
The Role of IGF-1R in Pediatric Malignancies
Oncologist, January 1, 2009; 14(1): 83 - 91.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Cao, Y. Yu, I. Darko, D. Currier, L. H. Mayeenuddin, X. Wan, C. Khanna, and L. J. Helman
Addiction to Elevated Insulin-like Growth Factor I Receptor and Initial Modulation of the AKT Pathway Define the Responsiveness of Rhabdomyosarcoma to the Targeting Antibody
Cancer Res., October 1, 2008; 68(19): 8039 - 8048.
[Abstract] [Full Text] [PDF]


Home page
aacredbookHome page
P. J Houghton, J. B Easton, and R. T Kurmasheva
mTOR as a Target for Cancer Therapy
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 111 - 120.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
F. C. Harwood, L. Shu, and P. J. Houghton
mTORC1 Signaling Can Regulate Growth Factor Activation of p44/42 Mitogen-activated Protein Kinases through Protein Phosphatase 2A
J. Biol. Chem., February 1, 2008; 283(5): 2575 - 2585.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. N. Prince, E. J. Foulstone, O. J. Zaccheo, C. Williams, and A. B. Hassan
Functional evaluation of novel soluble insulin-like growth factor (IGF)-II-specific ligand traps based on modified domain 11 of the human IGF2 receptor
Mol. Cancer Ther., February 1, 2007; 6(2): 607 - 617.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
D. H. Geho, R. W. Bandle, T. Clair, and L. A. Liotta
Physiological Mechanisms of Tumor-Cell Invasion and Migration
Physiology, June 1, 2005; 20(3): 194 - 200.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Scotlandi, M. C. Manara, G. Nicoletti, P.-L. Lollini, S. Lukas, S. Benini, S. Croci, S. Perdichizzi, D. Zambelli, M. Serra, et al.
Antitumor Activity of the Insulin-Like Growth Factor-I Receptor Kinase Inhibitor NVP-AEW541 in Musculoskeletal Tumors
Cancer Res., May 1, 2005; 65(9): 3868 - 3876.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
L-T Busund, E Richardsen, R Busund, T Ukkonen, T Bjornsen, C Busch, and H Stalsberg
Significant expression of IGFBP2 in breast cancer compared with benign lesions
J. Clin. Pathol., April 1, 2005; 58(4): 361 - 366.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. P. Dutcher
Mammalian Target of Rapamycin Inhibition
Clin. Cancer Res., September 15, 2004; 10(18): 6382S - 6387S.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Croci, L. Landuzzi, A. Astolfi, G. Nicoletti, A. Rosolen, F. Sartori, M. Y. Follo, N. Oliver, C. De Giovanni, P. Nanni, et al.
Inhibition of Connective Tissue Growth Factor (CTGF/CCN2) Expression Decreases the Survival and Myogenic Differentiation of Human Rhabdomyosarcoma Cells
Cancer Res., March 1, 2004; 64(5): 1730 - 1736.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Nanni, G. Nicoletti, C. De Giovanni, S. Croci, A. Astolfi, L. Landuzzi, E. Di Carlo, M. Iezzi, P. Musiani, and P.-L. Lollini
Development of Rhabdomyosarcoma in HER-2/neu Transgenic p53 Mutant Mice
Cancer Res., June 1, 2003; 63(11): 2728 - 2732.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
H. Cui, M. Cruz-Correa, F. M. Giardiello, D. F. Hutcheon, D. R. Kafonek, S. Brandenburg, Y. Wu, X. He, N. R. Powe, and A. P. Feinberg
Loss of IGF2 Imprinting: A Potential Marker of Colorectal Cancer Risk
Science, March 14, 2003; 299(5613): 1753 - 1755.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Huang, L. N. Liu, H. Hosoi, M. B. Dilling, T. Shikata, and P. J. Houghton
p53/p21CIP1 Cooperate in Enforcing Rapamycin-induced G1 Arrest and Determine the Cellular Response to Rapamycin
Cancer Res., April 1, 2001; 61(8): 3373 - 3381.
[Abstract] [Full Text]


Home page
Mol. Cell. Biol.Home page
W. J. Fredericks, K. Ayyanathan, M. Herlyn, J. R. Friedman, and F. J. Rauscher III
An Engineered PAX3-KRAB Transcriptional Repressor Inhibits the Malignant Phenotype of Alveolar Rhabdomyosarcoma Cells Harboring the Endogenous PAX3-FKHR Oncogene
Mol. Cell. Biol., July 15, 2000; 20(14): 5019 - 5031.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Khan, M. L. Bittner, L. H. Saal, U. Teichmann, D. O. Azorsa, G. C. Gooden, W. J. Pavan, J. M. Trent, and P. S. Meltzer
cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene
PNAS, November 9, 1999; 96(23): 13264 - 13269.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Hosoi, M. B. Dilling, T. Shikata, L. N. Liu, L. Shu, R. A. Ashmun, G. S. Germain, R. T. Abraham, and P. J. Houghton
Rapamycin Causes Poorly Reversible Inhibition of mTOR and Induces p53-independent Apoptosis in Human Rhabdomyosarcoma Cells
Cancer Res., February 1, 1999; 59(4): 886 - 894.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
R. Dagher and L. Helman
Rhabdomyosarcoma: An Overview
Oncologist, February 1, 1999; 4(1): 34 - 44.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
H. Hosoi, M. B. Dilling, L. N. Liu, M. K. Danks, T. Shikata, A. Sekulic, R. T. Abraham, J. C. Lawrence Jr., and P. J. Houghton
Studies on the Mechanism of Resistance to Rapamycin in Human Cancer Cells
Mol. Pharmacol., November 1, 1998; 54(5): 815 - 824.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
N. Lamharzi, A. V. Schally, M. Koppan, and K. Groot
Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors
PNAS, July 21, 1998; 95(15): 8864 - 8868.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
S. Zhan, D. Shapiro, S. Zhan, L. Zhang, S. Hirschfeld, J. Elassal, and L. J. Helman
Concordant Loss of Imprinting of the Human Insulin-like Growth Factor II Gene Promoters in Cancer
J. Biol. Chem., November 24, 1995; 270(47): 27983 - 27986.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
S. Bellusci, G. Moens, J. P. Thiery, and J. Jouanneau
A scatter factor-like factor is produced by a metastatic variant of a rat bladder carcinoma cell line
J. Cell Sci., May 1, 1994; 107(5): 1277 - 1287.
[Abstract] [PDF]


Home page
Cold Spring Harb Symp Quant BiolHome page
A.P. Feinberg, L.M. Kalikin, L.A. Johnson, and J.S. Thompson
Loss of Imprinting in Human Cancer
Cold Spring Harb Symp Quant Biol, January 1, 1994; 59(0): 357 - 364.
[Abstract] [PDF]


Home page
J. Cell Sci.Home page
M. A. Matthay, J. P. Thiery, F. Lafont, F. Stampfer, and B. Boyer
Transient effect of epidermal growth factor on the motility of an immortalized mammary epithelial cell line
J. Cell Sci., November 1, 1993; 106(3): 869 - 878.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1990 by the American Association of Cancer Research.